# EDGAR Filing Document

**Accession Number:** 0001584371
**File Stem:** 0001214659-26-003867
**Filing Date:** 2026-3
**Character Count:** 9719
**Document Hash:** fb3ec1c2c2d0bf5a673f5dc7bbfcfa71
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-26-003867.hdr.sgml**: 20260327

**ACCESSION NUMBER**: 0001214659-26-003867

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260327

**DATE AS OF CHANGE**: 20260327

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IceCure Medical Ltd.
- **CENTRAL INDEX KEY:** 0001584371
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92815
- **FILM NUMBER:** 26800786

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7 HA'ESHEL ST., POB 3163
- **CITY:** CAESAREA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 38900
- **BUSINESS PHONE:** 972-4-6230333

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7 HA'ESHEL ST., POB 3163
- **CITY:** CAESAREA
- **PROVINCE COUNTRY:** L3
- **ZIP:** 38900
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Haixiang Li
- **CENTRAL INDEX KEY:** 0002067600

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** STE 7013, 70F 2 INTERNATIONAL FIN CENTRE
- **STREET 2:** 8 FINANCE STREET
- **CITY:** CENTRAL, HONG KONG
- **PROVINCE COUNTRY:** K3
- **ZIP:** NULL

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**ICECURE MEDICAL LTD.**

*(Name of Issuer)*

**Ordinary Shares, no par value**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Li Haixiang**<br>Ste 7013, 70F Two IFC<br>8 Finance St<br>Hong Kong K3 518000<br>852 2385-8822

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/17/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Mr. Li Haixiang** | Name of reporting person<br>**Mr. Li Haixiang** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**HONG KONG** | Citizenship or place of organization<br>**HONG KONG** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**35846597.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**35846597.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**35846597.00** | Aggregate amount beneficially owned by each reporting person<br>**35846597.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**45.8%** | Percent of class represented by amount in Row (11)<br>**45.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** See Item 5 for beneficial ownership information of the Reporting Person. The percentage above is based on 73,122,293 Ordinary Shares of the Issuer that were outstanding as of December 31, 2025, based on information contained in the annual report on Form 20-F for the fiscal year ended December 31, 2025, filed by the Issuer on March 17, 2026.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Epoch Partner Investments Limited** | Name of reporting person<br>**Epoch Partner Investments Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D8** | Citizenship or place of organization<br>**D8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**35846597.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**35846597.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**35846597.00** | Aggregate amount beneficially owned by each reporting person<br>**35846597.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**45.8%** | Percent of class represented by amount in Row (11)<br>**45.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** See Item 5 for beneficial ownership information of the Reporting Person. The percentage above is based on 73,122,293 Ordinary Shares of the Issuer that were outstanding as of December 31, 2025, based on information contained in the annual report on Form 20-F for the fiscal year ended December 31, 2025, filed by the Issuer on March 17, 2026.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, no par value

**(b) Name of Issuer:**
ICECURE MEDICAL LTD.

**(c) Address of Issuer's Principal Executive Offices:**
7 Ha Eshel Street, P.O. Box 3163, Caesarea, L3, 3079504

This Amendment No. 1 to Schedule 13D (this "Schedule 13D/A"), which amends and supplements the Schedule 13D initially filed with the Securities and Exchange Commission (the "SEC") on May 14, 2025 (the "Schedule 13D"), by Epoch Partner Investments Limited ("Epoch") and Mr. Li Haixiang (collectively, the "Reporting Persons"), relates to the ordinary shares, no par value per share (the "Ordinary Shares"), of IceCure Medical Ltd., an Israeli company (the "Issuer"). This Schedule 13D/A is being filed to reflect that Mr. Li Haixiang resigned as a member of the Issuer's board of directors on March 17, 2026.

**Item 4. Purpose of Transaction**

This item is not being amended by this Schedule 13D/A.

**Item 5. Interest in Securities of the Issuer**

**(a)**
"Item 5. Interest in Securities of the Issuer" of the Schedule 13D is hereby amended and restated as follows:

The aggregate percentage of Ordinary Shares reported owned by the Reporting Persons is based upon 73,122,293 Ordinary Shares outstanding as of December 31, 2025, as reported by the Issuer on March 17, 2026. The Reporting Persons are deemed to beneficially own an aggregate of 30,846,597 Ordinary Shares, representing approximately 45.8% of the outstanding Ordinary Shares.

**(b)**
"Item 5. Interest in Securities of the Issuer" of the Schedule 13D is hereby amended and restated as follows:

The Reporting Persons hold shared voting and dispositive power over all of the Ordinary Shares that the Reporting Persons beneficially owned as of December 31, 2025.

Epoch directly holds the Ordinary Shares reported herein. Mr. Li Haixiang's beneficial ownership of the Issuer's securities arises solely from his position as the sole director of Epoch.

**(c)**
The Reporting Persons have not effected any transactions in the Ordinary Shares of the Issuer in the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

This item is not being amended by this Schedule 13D/A.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Mr. Li Haixiang

**Signature:** /s/ Li Haixiang

**Name/Title:** Li Haixiang

**Date:** 03/27/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Epoch Partner Investments Limited

**Signature:** /s/ Li Haixiang on behalf of Epoch Partner Investments Limited

**Name/Title:** Li Haixiang, Director

**Date:** 03/27/2026